The chimeric antigen receptor T-cell product JCAR017 continues to show promise in treating pediatric acute lymphoblastic leukemia patients, according to a press release from Juno Therapeutics.
In an ongoing phase I trial, 20 of 22 patients with relapsed/refractory CD 19 positive acute lymphoblastic (ALL) achieved complete remission. Remissions were found both in patients who previously had undergone some kind of therapy and in patients with untreated infantile ALL. Instances of severe cytokine release syndrome and/or severe neurotoxicity were seen in eight patients. While four relapses were observed, only one was CD 19 positive.
“These data provide valuable translational insights into the biology of our therapies, furthering our mission of developing innovative cellular therapeutic treatments to redirect the immune system to fight cancer. Given the impressive clinical results with this defined cell product candidate, we are encouraged to begin testing of JCAR017 in adult patients with B cell malignancies, including non-Hodgkin lymphoma, later this year,” Hans Bishop , CEO of Juno Therapeutics, said in the press release.
Find the full press release on the Juno Therapeutics website.
